The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise

Completed

• Conditions: Obesity
• Interventions: Other: subcutaneous adipose tissue microdialysis under local beta/alpha blockade

• Registration Number: NCT02418728
• Lead Sponsor: Hasselt University

Brief Summary

In the developing countries, obesity prevalence is on a dramatic rise. Obesity is related to co-morbidities and as a result, obesity significantly shortens life expectancy and lowers quality of life. To prevent this, participation in exercise or training programs is absolutely necessary, in order to generate adipose tissue mass loss. The amount of adipose tissue mass loss is, amongst others, dependent on lipolysis which is under endocrine regulation by, mainly, catecholamines, insulin and atrial natriuretic peptide. However, large variations in adipose tissue mass loss and gain are likely in obese subjects, possibly due to a decreased lipolytic effect of these hormones (as was shown for catecholamines in the subcutaneous adipose tissue of obese subjects). However, the relative contribution of atrial natriuretic peptide in the lipolytic process remains elusive, particularly in subjects with obesity, which show an increased plasma expression of atrial natriuretic peptide.

The aim of the present study is to observe the contribution of atrial natriuretic peptide in the subcutaneous adipose tissue of obese subjects. This will be tested by measurements of extracellular glycerol levels (by microdialysis) in the subcutaneous adipose tissue in situ at rest and during endurance exercise under local beta- and alpha-blockade.

Eventually, the knowledge gained from this research will contribute to the optimization of exercise programs for people with obesity.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-08
• Study First Submitted: 2015-03-17
• Study First Submitted QC: 2015-04-13
• Study First Posted: 2015-04-16
• Primary Completion: 2016-08
• Status Verified: 2016-11
• Study Completion: 2016-11
• Last Update Submitted: 2016-11-17
• Last Update Posted: 2016-11-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

• Obese group: BMI > 30 kg/m², sedentary (no regular physical activity last 6 months), insulin sensitive or insulin resistant
• Lean controls: BMI > 18.5 kg/m² and < 25 kg/m², regular physical activity, insulin sensitive

Exclusion Criteria

• Regular glucose lowering medication or beta blockade medication
• Presence of chronical diseases
• Orthopedic or neurological problems

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
persons with obesity	subcutaneous adipose tissue microdialysis under local beta/alpha blockade	-
lean persons	subcutaneous adipose tissue microdialysis under local beta/alpha blockade	-

Primary Outcome Measures

Name	Time	Method
Atrial natriuretic peptide (ANP) Response	week 1	measurement systemic ANP response (venous blood sampling)
Subcutaneous adipose tissue microdialysis	week 1	abdominal subcutaneous adipose tissue microdialysis during rest and exercise; basal + under local alpha- and beta-blockade.

Secondary Outcome Measures

Name	Time	Method
Central insulin sensitivity	screening	Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g)
Echocardiography	Day 1	heart function by means of standard echocardiography
Maximal oxygen uptake (ml/O2/kg/min)	Day 1	measured using indirect calorimetry and an incremental bicycle protocol
Anthropometry	screening	body composition, measured using dual x-ray absorptiometry, height, weight, waist and hip circumference
Abdominal subcutaneous adipose tissue biopsy	week 1	biochemical, proteomics and morphological analyses

Trial Locations

Locations (1)

Hasselt University; 🇧🇪 Diepenbeek, Belgium